Migraine Trial, Recruiting NCT06796725 Sponsor: Ruijin Hospital Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06796725
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have headaches on at least 15 days per month, and this pattern has been ongoing for at least 3 months, where those headaches have features of tension-type headaches or migraines
  • People who have had at least 5 headache episodes that meet the recognised medical criteria for migraine (either with or without aura — that is, with or without warning symptoms like visual disturbances)
  • People whose headaches, on more than 8 days per month for over 3 months, either have typical migraine features, or are relieved by taking migraine medications such as triptans or ergot-based treatments
  • People who are able to swallow tablets
  • People who have signed a consent form and are willing to follow all study procedures throughout the trial

Who may not be able to join:

  • People under 15 years of age
  • People who have swelling at the back of the eye (optic disc oedema), neurological symptoms or signs (other than typical migraine aura such as visual or sensory warnings), or problems with memory or thinking
  • People whose headaches come on suddenly and reach peak intensity very quickly (sometimes called "thunderclap headaches")
  • People whose headaches occur alongside a fever
  • People over 50 years of age whose headaches are newly developed
  • People with a high risk of blood clotting who experience headaches
  • People with a history of cancer or HIV/AIDS who have developed new headaches
  • People whose headaches change depending on body position
  • People with a history of epileptic seizures

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-21-64370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
6 February 2025
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Headache Scale Reduction Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov